NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

34.59M

Vuru Grade

23.16/100

Current Price

$0.67
-0.04 (-5.63%)

Stability Price

$0.28
Overvalued by 57.65%

Company Metrics

  • 0 P/E
  • 34.16 P/S
  • 6.40 P/B
  • -0.32 EPS
  • -2,078.99% Cash ROIC
  • 1.62 Cash Ratio
  • 0 / N/A % Dividend
  • 232,977.00 Avg. Vol.
  • 51.63M Shares
  • 34.59M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Reports 2014 Fourth Quarter and Full Year Financial ...
Business Wire (press release) - Mar 26, 2015
BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three ...
NovaBay Pharmaceuticals (NBY) Releases Quarterly Earnings Results, Misses ... - Dakota Financial News
NovaBay raises $4.9M in a private placement (NBY)
Seeking Alpha (registration) - Mar 4, 2015
The company's largest shareholder, China Pioneer Pharma, will purchase units at $0.60, as will NovaBay CEO Ron Najafi, Ph.
NovaBay Announces $4.9 Million Private Placement - MarketWatch
Novabay Pharmaceuticals, Inc. Files SEC Form SC 13G, Statement of ...
Insurance News Net - Feb 20, 2015
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
NovaBay revamps strategy to focus on Eye Care (NBY)
Seeking Alpha - Jan 7, 2015
NovaBay Pharmaceuticals (NYSEMKT:NBY) refines its business strategy in order to focus on the eye care market. Its initiative consists of three main components: Drive revenue growth by by expanding the sales and marketing organization.
NovaBay Announces New Business Strategy Focusing on Products for Eye Care - Yahoo Finance UK
Short Interest in NovaBay Pharmaceuticals Expands By 144.5% (NBY)
Dakota Financial News - Mar 25, 2015
NovaBay Pharmaceuticals (NYSE:NBY) traded up 9.09% on Tuesday, hitting $0.72. 958,832 shares of the company's stock traded hands.
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common ...
GlobeNewswire (press release) - Mar 20, 2014
EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an ...
NovaBay Pharmaceuticals, Inc. Short Interest Disclosure
Bar and Graph Report - Mar 12, 2015
The short interest in NovaBay Pharmaceuticals has increased from 553,026 on February 13,2015 to 557,107 on February 27,2015.
Short Interest in NovaBay Pharmaceuticals Decreases By 1.6% (NBY) - Dakota Financial News
Short Interest in NovaBay Pharmaceuticals Declines By 1.6% (NBY) - WKRB News
NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth
Business Wire (press release) - Mar 16, 2015
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today provided an update on its commercial ...
Stocks Alert - NovaBay Pharmaceuticals (NBY) RMG Networks (RMGN ...
Markets Emerging - Mar 25, 2015
NovaBay® Pharmaceuticals, Inc. (NYSEMKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products for the global eye care market, declared that Avenova™, the company's eyelid ...
NovaBay Pharmaceuticals, Inc. (NBY): NVC-422 Gives NovaBay Huge Growth ...
Seeking Alpha - Dec 9, 2013
NovaBay (NBY) is a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products.